Myelin basic protein and its diagnostic value in HIV-infected individuals with 4th clinical stage and neuroinfections

Authors

DOI:

https://doi.org/10.15587/2519-4798.2021.228189

Keywords:

HIV-infection, myelin basic protein, opportunistic infections, central nervous system

Abstract

It was shown that in HIV-infected patients, pathomorphological changes in the white matter in the form of demyelinization are already observed in the early stages of the disease. The most studied marker of this process is myelin basic protein that can be detected in cerebrospinal fluid or serum immediately after acute myelin breakdown.

The aim. To assess the diagnostic value of myelin basic protein content in serum and cerebrospinal fluid of HIV-infected individuals with 4th clinical stage and central nervous system opportunistic infections.

Materials and methods. Using ELISA with diagnostic kit “MBP ELISA” (Ansh Labs, USA), we studied the myelin basic protein content in serum and cerebrospinal fluid of 53 HIV-infected patients with 4th clinical stage and central nervous system opportunistic infections depending on its etiology, the outcome of the diseases and according to Glasgow coma scale score. As well correlation analysis with some laboratory and clinical indicators was performed.

Results. We found significantly increased myelin basic protein content in both cerebrospinal fluid and serum of HIV-infected patients 4th clinical stage with central nervous system opportunistic infections compared to control (p˂0.01), which indicate the presence of active demyelinization in central nervous system. The highest cerebrospinal fluid myelin basic protein was registered in patients with an unfavourable outcome of the disease, as death or residual neurologic deficit, and patients with cerebral toxoplasmosis. The cerebrospinal fluid myelin basic protein had an association with the size of white matter lesions on magnetic resonance imaging and serum myelin basic protein content.

Conclusions. Myelin basic protein detection in cerebrospinal fluid as well as in serum can serve as an additional quantitative marker of myelin disruption, which can be used along with magnetic resonance imaging for the diagnosis improvement and prognosis of central nervous system opportunistic infections in HIV-infected individuals with 4th clinical stage

Author Biographies

Volodymyr Kozko, Kharkiv National Medical University

MD, Professor

Department of Pediatric Infectious Diseases

Maryna Hvozdetska-Shaar , Kharkiv National Medical University

Assistant

Department of Infectious Diseases

Anton Sokhan, Kharkiv National Medical University

MD, Associate professor

Department of Infectious Diseases

Kateryna Yurko, Kharkiv National Medical University

MD, Professor

Department of Infectious Diseases

Ganna Solomennyk, Kharkiv National Medical University

PhD, Associate professor

Department of Infectious Diseases

References

  1. Modi, G., Mochan, A., Modi, M. (2018). Neurological Manifestations of HIV. Advances in HIV and AIDS Control. doi: http://doi.org/10.5772/intechopen.80054
  2. Bowen, L. N., Smith, B., Reich, D., Quezado, M., Nath, A. (2016). HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment. Nature Reviews Neurology, 12 (11), 662–674. doi: http://doi.org/10.1038/nrneurol.2016.149
  3. Farhadian, S., Patel, P., Spudich, S. (2017). Neurological Complications of HIV Infection. Current Infectious Disease Reports, 19 (12). doi: http://doi.org/10.1007/s11908-017-0606-5
  4. Wang, B., Liu, Z., Liu, J., Tang, Z., Li, H., Tian, J. (2015). Gray and white matter alterations in early HIV-infected patients: Combined voxel-based morphometry and tract-based spatial statistics. Journal of Magnetic Resonance Imaging, 43 (6), 1474–1483. doi: http://doi.org/10.1002/jmri.25100
  5. Vassall, K. A., Bamm, V. V., Harauz, G. (2015). MyelStones: the executive roles of myelin basic protein in myelin assembly and destabilization in multiple sclerosis. Biochemical Journal, 472 (1), 17–32. doi: http://doi.org/10.1042/bj20150710
  6. Armstrong, R. C., Mierzwa, A. J., Sullivan, G. M., Sanchez, M. A. (2016). Myelin and oligodendrocyte lineage cells in white matter pathology and plasticity after traumatic brain injury. Neuropharmacology, 110, 654–659. doi: http://doi.org/10.1016/j.neuropharm.2015.04.029
  7. Yang, L., Tan, D., Piao, H. (2016). Myelin Basic Protein Citrullination in Multiple Sclerosis: A Potential Therapeutic Target for the Pathology. Neurochemical Research, 41 (8), 1845–1856. doi: http://doi.org/10.1007/s11064-016-1920-2
  8. Zhang, J., Sun, X., Zheng, S., Liu, X., Jin, J., Ren, Y., Luo, J. (2014). Myelin Basic Protein Induces Neuron-Specific Toxicity by Directly Damaging the Neuronal Plasma Membrane. PLoS ONE, 9 (9), e108646. doi: http://doi.org/10.1371/journal.pone.0108646
  9. Lamers, K. J. B., Van Engelen, B. G. M., Gabreëls, F. J. M., Hommes, O. R., Borm, G. F., Wevers, R. A. (2009). Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders. Acta Neurologica Scandinavica, 92 (3), 247–251. doi: http://doi.org/10.1111/j.1600-0404.1995.tb01696.x
  10. Borg, K., Bonomo, J., Jauch, E. C., Kupchak, P., Stanton, E. B., Sawadsky, B. (2012). Serum Levels of Biochemical Markers of Traumatic Brain Injury. ISRN Emergency Medicine, 2012, 1–7. doi: http://doi.org/10.5402/2012/417313
  11. Sokhan, A., Zots, Y., Gavrylov, A., Iurko, K., Solomennik, A., Kuznietsova, A. (2017). Levels of neurospecific markers in cerebrospinal fluid of adult patients with bacterial meningitis. Georgian Med News, 270, 65–69.
  12. Liuzzi, G. M., Mastroianni, C. M., Vullo, V., Jirillo, E., Delia, S., Riccio, P. (1992). Cerebrospinal fluid myelin basic protein as predictive marker of demyelination in AIDS dementia complex. Journal of Neuroimmunology, 36 (2-3), 251–254. doi: http://doi.org/10.1016/0165-5728(92)90058-s
  13. O’Connor, E., Zeffiro, T. (2019). Is treated HIV infection still toxic to the brain? Brain Imaging, 165, 259–284. doi: http://doi.org/10.1016/bs.pmbts.2019.04.001
  14. Le, L., Spudich, S. (2016). HIV-Associated Neurologic Disorders and Central Nervous System Opportunistic Infections in HIV. Seminars in Neurology, 36 (04), 373–381. doi: http://doi.org/10.1055/s-0036-1585454
  15. Lуtvуn, K. Y. (2018). Diagnostic significance of the determination of myelin basic protein in cerebrospinal fluid in HIV-associated neurological diseases. Medical Perspectives, 23 (2), 71–78. doi: http://doi.org/10.26641/2307-0404.2018.2.133941
  16. De Vries, J., Thijssen, W. A. M. H., Snels, S. E. A., Menovsky, T., Peer, N. G., Lamers, K. J. (2001). Intraoperative values of S-100 protein, myelin basic protein, lactate, and albumin in the CSF and serum of neurosurgical patients. Journal of Neurology, Neurosurgery & Psychiatry, 71 (5), 671–674. doi: http://doi.org/10.1136/jnnp.71.5.671
  17. Nakagawa, H., Yamada, M., Kanayama, T., Tsuruzono, K., Miyawaki, Y., Tokiyoshi, K. et. al. (1994). Myelin Basic Protein in the Cerebrospinal Fluid of Patients with Brain Tumors. Neurosurgery, 34 (5), 825–833. doi: http://doi.org/10.1227/00006123-199405000-00006
  18. Neryanova, Y. N. (2014). Diagnostic value of brain damage markers levels in serum during the first 24 hours of the brain ischemic stroke. Zaporozhye Medical Journal, 6 (87), 48–51. doi: http://doi.org/10.14739/2310-1210.2014.6.35764
  19. Kawata, K., Liu, C. Y., Merkel, S. F., Ramirez, S. H., Tierney, R. T., Langford, D. (2016). Blood biomarkers for brain injury: What are we measuring? Neuroscience & Biobehavioral Reviews, 68, 460–473. doi: http://doi.org/10.1016/j.neubiorev.2016.05.009
  20. Van Engelen, B. G., Lamers, K. J., Gabreels, F. J., Wevers, R. A., van Geel, W. J., Borm, G. F. (1992). Age-Related Changes of Neuron-Specific Enolase, S-100 Protein, and Myelin Basic Protein Concentrations in Cerebrospinal Fluid. Clinical Chemistry, 38 (6), 813–816. doi: http://doi.org/10.1093/clinchem/38.6.813

Downloads

Published

2021-04-05

How to Cite

Kozko, V., Hvozdetska-Shaar , M., Sokhan, A., Yurko, K., & Solomennyk, G. (2021). Myelin basic protein and its diagnostic value in HIV-infected individuals with 4th clinical stage and neuroinfections. ScienceRise: Medical Science, (2(41), 28–32. https://doi.org/10.15587/2519-4798.2021.228189

Issue

No. 2(41) (2021)

Section

Medical Science

License

Copyright (c) 2021 Volodymyr Kozko, Maryna Hvozdetska-Shaar , Anton Sokhan, Kateryna Yurko, Ganna Solomennyk

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.